VC
ABBV icon

Vicus Capital’s AbbVie ABBV Stock Holding History

Vicus Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$696K Sell
3,202
-427
-12% -$94.7K 0.05% 150
2025
Q4 		$829K Sell
3,629
-353
-9% -$80.4K 0.06% 134
2025
Q3 		$922K Buy
3,982
+73
+2% +$14.9K 0.07% 122
2025
Q2 		$726K Buy
3,909
+779
+25% +$145K 0.06% 120
2025
Q1 		$656K Buy
3,130
+307
+11% +$59.7K 0.06% 116
2024
Q4 		$502K Sell
2,823
-524
-16% -$96.3K 0.04% 135
2024
Q3 		$661K Buy
3,347
+332
+11% +$62K 0.06% 121
2024
Q2 		$517K Buy
3,015
+738
+32% +$122K 0.05% 154
2024
Q1 		$415K Sell
2,277
-393
-15% -$67.7K 0.04% 171
2023
Q4 		$414K Sell
2,670
-845
-24% -$123K 0.04% 146
2023
Q3 		$524K Buy
3,515
+115
+3% +$16.9K 0.05% 141
2023
Q2 		$458K Sell
3,400
-1,301
-28% -$191K 0.05% 139
2023
Q1 		$749K Sell
4,701
-1,189
-20% -$182K 0.08% 107
2022
Q4 		$952K Sell
5,890
-1,800
-23% -$276K 0.11% 93
2022
Q3 		$1.03M Buy
7,690
+837
+12% +$120K 0.12% 92
2022
Q2 		$1.05M Buy
6,853
+731
+12% +$112K 0.12% 95
2022
Q1 		$992K Sell
6,122
-46
-0.7% -$6.68K 0.1% 110
2021
Q4 		$855K Buy
+6,168
New +$729K 0.09% 114
2021
Q2 		– Sell
-6,300
Closed -$682K – 153
2021
Q1 		$682K Buy
6,300
+43
+0.7% +$4.6K 0.08% 125
2020
Q4 		$670K Sell
6,257
-595
-9% -$57.2K 0.08% 120
2020
Q3 		$600K Buy
6,852
+109
+2% +$10.3K 0.09% 115
2020
Q2 		$662K Buy
6,743
+552
+9% +$48.6K 0.1% 105
2020
Q1 		$472K Sell
6,191
-2,165
-26% -$184K 0.09% 111
2019
Q4 		$740K Sell
8,356
-2,701
-24% -$224K 0.11% 101
2019
Q3 		$837K Buy
11,057
+410
+4% +$28.1K 0.12% 113
2019
Q2 		$774K Buy
10,647
+2,118
+25% +$166K 0.11% 122
2019
Q1 		$687K Sell
8,529
-95
-1% -$7.77K 0.11% 122
2018
Q4 		$795K Sell
8,624
-144
-2% -$12.7K 0.14% 107
2018
Q3 		$829K Sell
8,768
-179
-2% -$17K 0.13% 108
2018
Q2 		$829K Sell
8,947
-751
-8% -$73.3K 0.14% 107
2018
Q1 		$918K Sell
9,698
-2,924
-23% -$321K 0.16% 101
2017
Q4 		$1.22M Sell
12,622
-1,063
-8% -$100K 0.21% 78
2017
Q3 		$1.22M Sell
13,685
-2,153
-14% -$164K 0.23% 80
2017
Q2 		$1.15M Buy
15,838
+1,527
+11% +$103K 0.23% 80
2017
Q1 		$932K Buy
14,311
+5,413
+61% +$340K 0.2% 94
2016
Q4 		$557K Buy
8,898
+2,285
+35% +$139K 0.12% 131
2016
Q3 		$417K Sell
6,613
-4,426
-40% -$287K 0.09% 147
2016
Q2 		$683K Buy
11,039
+5,123
+87% +$312K 0.17% 101
2016
Q1 		$338K Buy
5,916
+1,557
+36% +$86.8K 0.08% 137
2015
Q4 		$258K Buy
+4,359
New +$251K 0.07% 167
2015
Q3 		– Sell
-3,330
Closed -$224K – 184
2015
Q2 		$224K Buy
+3,330
New +$217K 0.06% 162
2015
Q1 		– Sell
-3,726
Closed -$244K – 190
2014
Q4 		$244K Buy
3,726
+2
+0.1% +$126 0.07% 145
2014
Q3 		$215K Buy
+3,724
New +$207K 0.07% 139

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vicus Capital's ABBV Position: Q1 2026 in Review

Vicus Capital reduced its AbbVie (ABBV) stake by 12% in Q1 2026, selling an estimated $94.7K and leaving 3,202 shares worth $696K. The position accounts for 0.05% of the portfolio, ranked #150.

Vicus Capital first reported a position in ABBV in Q3 2014 and has held it in 43 quarters since. The position peaked at $1.22M in Q4 2017. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Vicus Capital held 3,202 shares of AbbVie worth $696K as of Q1 2026.
  • Vicus Capital sold 427 AbbVie shares in Q1 2026, an estimated $94.7K.
  • AbbVie made up 0.05% of Vicus Capital's portfolio in Q1 2026, its #150 holding.
  • Vicus Capital first reported a position in AbbVie in Q3 2014 and has held it in 43 quarters since.
  • Vicus Capital's AbbVie position peaked at $1.22M in Q4 2017.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Vicus Capital's 13F filing for Q1 2026, filed 22 Apr 2026.